Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955897 · ClinicalTrials.gov registry record
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
A clinical trial of Spinal Muscular Atrophy, sponsored by Columbia University.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06955897 is a study of Spinal Muscular Atrophy that is actively recruiting participants, run by Columbia University. The registered enrollment target is 45 participants, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06955897, a study of Spinal Muscular Atrophy, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse cohort of people with SMA (pwSMA) and evaluate the change of PPF before and after nusinersen dosing.
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-04-24 |
| Est. Completion | 2027-02-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06955897
The ClinicalTrials.gov registry entry for NCT06955897 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (58% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06955897 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06955897 about?
NCT06955897 is a clinical study titled "Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA". The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse...
What is the current status of trial NCT06955897?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2025-04-24. Estimated completion is 2027-02-26.
What conditions does trial NCT06955897 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy.
What interventions are being tested in trial NCT06955897?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06955897?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955897 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
RECRUITING · NA
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
RECRUITING
-
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.